Trial Profile
Single arm single Center Clinical study of Apatinib Mesylate in the treatment of malignant brain Metastases with peritumoral edema after radiotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Brain metastases; Brain oedema
- Focus Therapeutic Use
- 06 Sep 2018 New trial record